TerminatedNCT03351244
This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months
Medication studyAges 18–55Multiple countries
Understand this study
Who could participate?
Listed age limits: 18 years to 55 years.
- Listed locations
- Phoenix and 58 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: December 7, 2017
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 264
- Sponsor
- Boehringer Ingelheim
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, France, Canada, ...
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT03351244
- Official title
Show the full official title
A Phase II Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Orally Administered BI 409306 During a 28-week Treatment Period as Adjunctive Therapy to Antipsychotic Treatment for the Prevention of Relapse in Patients With Schizophrenia.
Recruitment & locations
TerminatedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Phoenix, United States · Costa Mesa, United States · Garden Grove, United States
52 more locations
- Glendale, United States
- Lemon Grove, United States
- Los Angeles, United States
- Oceanside, United States
- Orange, United States
- Torrance, United States
- Hallandale, United States
- Hialeah, United States
- Maitland, United States
- North Miami, United States
- Orlando, United States
- Atlanta, United States
- Chicago, United States
- Lake Charles, United States
- Monroe, United States
- Ann Arbor, United States
- Flowood, United States
- Saint Charles, United States
- St Louis, United States
- Las Vegas, United States
- Berlin, United States
- Cedarhurst, United States
- New York, United States
- Austin, United States
- Irving, United States
- Richardson, United States
- Richmond, United States
- Calgary, Canada
- Penticton, Canada
- Vancouver, Canada
- Chatham, Canada
- Toronto, Canada
- Montreal, Canada
- Montpellier, France
- Paris, France
- Rennes, France
- Saint-Priest-en-Jarez, France
- Toulon, France
- Aichi, Toyoake, Japan
- Chiba, Ichikawa, Japan
- Fukuoka, Fukuoka, Japan
- Kanagawa, Atsugi, Japan
- Kanagawa, Kawasaki, Japan
- Nara, Kashihara, Japan
- Saga, Kanzaki-gun, Japan
- Tokyo, Kodaira, Japan
- Gwangju, South Korea
- Seongnam, South Korea
- Seoul, South Korea
- Santander, Spain
- Tainan, Taiwan
- Taoyuan, Taiwan
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Boehringer Ingelheim.
Does this study involve medication?
Yes. The study involves medication, including BI 409306 and Placebo.
Who can participate?
Listed age limits: 18 years to 55 years.
Is this study still recruiting?
The registry lists this study as terminated.
